First Western Capital Management Co lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,704 shares of the medical research company’s stock after selling 364 shares during the period. First Western Capital Management Co’s holdings in Amgen were worth $638,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. River Wealth Advisors LLC boosted its holdings in shares of Amgen by 0.4% in the second quarter. River Wealth Advisors LLC now owns 14,772 shares of the medical research company’s stock valued at $2,544,000 after purchasing an additional 66 shares during the period. JFS Wealth Advisors LLC boosted its holdings in shares of Amgen by 10.9% in the second quarter. JFS Wealth Advisors LLC now owns 1,692 shares of the medical research company’s stock valued at $291,000 after purchasing an additional 166 shares during the period. Opus Investment Management Inc. boosted its holdings in shares of Amgen by 5.6% in the second quarter. Opus Investment Management Inc. now owns 37,600 shares of the medical research company’s stock valued at $6,476,000 after purchasing an additional 2,000 shares during the period. Kistler Tiffany Companies LLC boosted its holdings in shares of Amgen by 8.0% in the second quarter. Kistler Tiffany Companies LLC now owns 12,990 shares of the medical research company’s stock valued at $2,237,000 after purchasing an additional 962 shares during the period. Finally, Grove Bank & Trust boosted its holdings in shares of Amgen by 87.4% in the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 341 shares during the period. Institutional investors and hedge funds own 78.10% of the company’s stock.
AMGN has been the subject of a number of research reports. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a report on Friday, June 30th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $177.00 price target on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Morgan Stanley boosted their price target on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. Finally, Deutsche Bank AG reiterated a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a report on Wednesday, July 26th. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $189.99.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.19% of the stock is owned by insiders.
Amgen Inc. (NASDAQ:AMGN) opened at 185.79 on Wednesday. The firm has a market capitalization of $135.57 billion, a P/E ratio of 16.92 and a beta of 1.36. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The stock’s 50 day moving average price is $182.35 and its 200-day moving average price is $170.56.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company earned $2.84 earnings per share. Amgen’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post $12.58 earnings per share for the current year.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.